Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 28;15(2):494-506.
doi: 10.21037/jtd-22-919. Epub 2023 Feb 20.

Dyspnea in patients with stage IV non-small cell lung cancer: a population-based analysis of disease burden and patterns of care

Affiliations

Dyspnea in patients with stage IV non-small cell lung cancer: a population-based analysis of disease burden and patterns of care

Michael Yan et al. J Thorac Dis. .

Abstract

Background: Patients with metastatic non-small cell lung cancer (NSCLC) experience significant morbidity with dyspnea being a common symptom with a prevalence of 70%. The objective of this study was to determine factors associated with a moderate-to-severe dyspnea score based on the Edmonton Symptom Assessment System (ESAS), as well as resultant patterns of intervention and factors correlated to intervention receipt.

Methods: Using health services administrative data, we conducted a population-based study of all patients diagnosed with metastatic NSCLC treated from January 2007 to September 2018 in the province of Ontario. The primary outcomes of interest are the prevalence of moderate-to-severe dyspnea scores, and the receipt of dyspnea-directed intervention. Differences in baseline characteristic between moderate-to-severe dyspnea and low dyspnea score cohorts were assessed by comparative statistics. Predictors of intervention receipt for patients with moderate-to-severe dyspnea scores were estimated using multivariable modified Poisson regression.

Results: The initial study cohort included 13,159 patients diagnosed with metastatic NSCLC and of these, 9,434 (71.7%) reported a moderate-to-severe dyspnea score. Compared to patients who did not report moderate-to-severe dyspnea scores, those who reported a moderate-to-severe dyspnea score were more likely to complete a greater number of ESAS surveys, be male, have a higher Elixhauser comorbidity index (ECI) score, and receive subsequent systemic therapy after diagnosis. Most patients with a moderate-to-severe dyspnea score received intervention (96%), of which the most common were palliative care management (87%), thoracic radiotherapy (56%) and thoracentesis (37%). Multivariable regression identified older patients to be less likely to undergo pleurodesis. Thoracentesis was less common for patients living in rural and non-major urban areas, lower income areas, and earlier year of diagnosis. Receipt of thoracic radiotherapy was less common for older patients, females, those with ECI ≥4, patients living in major urban areas, and those with later year of diagnosis. Finally, palliative care referrals were less frequent for patients with ECI ≥4, age 60-69, residence outside of major urban areas, earlier year of diagnosis, and lower income areas.

Conclusions: Dyspnea is a prevalent symptom amongst patients with metastatic NSCLC. Subpopulations of patients with moderate-to-severe dyspnea scores were in which inequities may exist in access to care that require further attention and evaluation.

Keywords: Edmonton Symptom Assessment System (ESAS); Non-small cell lung cancer (NSCLC); dyspnea; metastatic; population-base.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-919/coif). AVL serves as an unpaid editorial board member of Journal of Thoracic Disease. MD reports consulting fees from Eisai, Boehringer Ingelheim, Roche, and Takeda, as well as consulting fees and research funding from Merck and AstraZeneca. JH reports honoraria from Ipsen and Advanced Accelerator Applications. BK reports being on the scientific advisory board for AstraZeneca. NGC reports honoraria from AstraZeneca. AVL reports honoraria from RefleXion, Varian Medical Systems, and AstraZeneca. The other authors have no conflicts of interest to declare.

References

    1. Whisenant MS, Williams LA, Garcia Gonzalez A, et al. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract 2020;16:e1151-60. 10.1200/JOP.19.00577 - DOI - PubMed
    1. Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 2010;5:29-33. 10.1097/JTO.0b013e3181c5920c - DOI - PubMed
    1. Iyer S, Roughley A, Rider A, et al. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer 2014;22:181-7. 10.1007/s00520-013-1959-4 - DOI - PubMed
    1. Kathiresan G, Clement RF, Sankaranarayanan MT. Dyspnea in lung cancer patients: a systematic review. Lung Cancer (Auckl) 2010;1:141-50. 10.2147/LCTT.S14426 - DOI - PMC - PubMed
    1. Nic Giolla Easpaig B, Tran Y, Bierbaum M, et al. What are the attitudes of health professionals regarding patient reported outcome measures (PROMs) in oncology practice? A mixed-method synthesis of the qualitative evidence. BMC Health Serv Res 2020;20:102. 10.1186/s12913-020-4939-7 - DOI - PMC - PubMed